Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Structure-Based Virtual Screening to Identify Novel Potential Compound as an Alternative to Remdesivir to Overcome the RdRp Protein Mutations in SARS-CoV-2

9 Apr 2021

Abstract excerpt

The number of confirmed COVID-19 cases is rapidly increasing with no direct treatment for the disease. Few repurposed drugs, such as Remdesivir, Chloroquine, Hydroxychloroquine, Lopinavir, and Ritonavir, are being tested against SARS-CoV-2. Remdesivir is the drug of choice for Ebola virus disease and has been authorized for emergency use. This drug acts against SARS-CoV-2 by inhibiting the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to COVID-19 Clinical Research Studies
Share to SARS-CoV-2 and COVID-19 Research
Share to Viral Infections and Outbreaks Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33898520
DOI: 10.3389/fmolb.2021.645216

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Structure-Based Virtual Screening to Identify Novel Potential Compound as an Alternative to Remdesivir to Overcome the RdRp Protein Mutations in SARS-CoV-2PMID 33898520Read ↗

Comparative inhibition analysis of wild type and G671S catalytic site mutant of the SARS-CoV-2 RNA-dependent RNA polymeraseSemantic proximity Read ↗

Binding properties of selective inhibitors of P323L mutated RdRp of SARS-CoV-2: a combined molecular screening, docking and dynamics simulation study.Semantic proximity Read ↗

Predicting Antiviral Resistance Mutations in SARS-CoV-2 Main Protease with Computational and Experimental Screening.Semantic proximity Read ↗

Virtual screening FDA approved drugs against multiple targets of SARS‐CoV‐2Semantic proximity Read ↗

A novel virtual screening procedure identifies Pralatrexate as inhibitor of SARS-CoV-2 RdRp and it reduces viral replication in vitroSemantic proximity Read ↗

High-throughput rational design of the remdesivir binding site in the RdRp of SARS-CoV-2: implications for potential resistanceSemantic proximity Read ↗

A computational approach to drug repurposing against SARS-CoV-2 RNA dependent RNA polymerase (RdRp)Semantic proximity Read ↗

Potential RNA-dependent RNA polymerase inhibitors as prospective therapeutics against SARS-CoV-2Semantic proximity Read ↗

In Silico Drug Discovery: The Next Frontier in the Fight Against SARS-CoV-2Semantic proximity Read ↗

Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbation-based virtual screening of existing drugsSemantic proximity Read ↗

Prediction of binding of FDA approved drug Ledipasvir to SARS-CoV2 mutants: an in silico studySemantic proximity Read ↗

Identification of Potential Antiviral Lead Inhibitors Against Sars-Cov-2 Main Protease: Structure-Guided Virtual Screening, Docking, Adme, and Md Simulation Based ApproachSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.